171 related articles for article (PubMed ID: 34876272)
21. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
22. [A standardized medical report template for CAR T-Cell therapy patients: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Broussais F; Vasseur A; Karam M; Chaillou D; Pereira M; Yakoub-Agha I; Raus N
Bull Cancer; 2021 Dec; 108(12S):S82-S86. PubMed ID: 33933288
[TBL] [Abstract][Full Text] [Related]
23. Driving the CAR to the Bone Marrow Transplant Program.
Dave H; Jerkins L; Hanley PJ; Bollard CM; Jacobsohn D
Curr Hematol Malig Rep; 2019 Dec; 14(6):561-569. PubMed ID: 31643018
[TBL] [Abstract][Full Text] [Related]
24. [Multidrug-resistant bacteria detection in patients undergoing allogeneic hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Brissot E; Villate A; Alsuliman T; Beauvais D; Bonnin A; Mear JB; Souchet L; Yakoub-Agha I; Bazarbachi A
Bull Cancer; 2020 Jan; 107(1S):S7-S11. PubMed ID: 31635753
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
26. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
27. Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.
Hong R; Zhao H; Wang Y; Chen Y; Cai H; Hu Y; Wei G; Huang H
Bone Marrow Transplant; 2021 Mar; 56(3):570-580. PubMed ID: 32943758
[TBL] [Abstract][Full Text] [Related]
28. CAR-T cell therapy and infection: a review.
Bupha-Intr O; Haeusler G; Chee L; Thursky K; Slavin M; Teh B
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):749-758. PubMed ID: 33249873
[No Abstract] [Full Text] [Related]
29. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
30. Reactions Related to CAR-T Cell Therapy.
Miao L; Zhang Z; Ren Z; Li Y
Front Immunol; 2021; 12():663201. PubMed ID: 33995389
[TBL] [Abstract][Full Text] [Related]
31. Prevention and treatment of cancer-related infections.
Baden LR; Bensinger W; Angarone M; Casper C; Dubberke ER; Freifeld AG; Garzon R; Greene JN; Greer JP; Ito JI; Karp JE; Kaul DR; King E; Mackler E; Marr KA; Montoya JG; Morris-Engemann A; Pappas PG; Rolston K; Segal B; Seo SK; Swaminathan S; Naganuma M; Shead DA;
J Natl Compr Canc Netw; 2012 Nov; 10(11):1412-45. PubMed ID: 23138169
[TBL] [Abstract][Full Text] [Related]
32. Prevention of infections in bone marrow transplant recipients.
Serody JS; Shea TC
Infect Dis Clin North Am; 1997 Jun; 11(2):459-77. PubMed ID: 9187956
[TBL] [Abstract][Full Text] [Related]
33. Infectious complications and vaccines.
Ljungman P
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):587-591. PubMed ID: 34889437
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
35. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
36. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
Chakraborty R; Sidana S; Shah GL; Scordo M; Hamilton BK; Majhail NS
Biol Blood Marrow Transplant; 2019 May; 25(5):e155-e162. PubMed ID: 30500439
[TBL] [Abstract][Full Text] [Related]
37. How I treat cytopenias after CAR T-cell therapy.
Jain T; Olson TS; Locke FL
Blood; 2023 May; 141(20):2460-2469. PubMed ID: 36800563
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
Gudiol C; Lewis RE; Strati P; Kontoyiannis DP
Lancet Haematol; 2021 Mar; 8(3):e216-e228. PubMed ID: 33460558
[TBL] [Abstract][Full Text] [Related]
39. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
40. [Vaccination before and after autologous hematopoietic cell transplantation for autoimmune diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (MATHEC-SFGM-TC)].
Maria ATJ; Campidelli A; Castilla-Llorente C; Lansiaux P; Marjanovic Z; Pugnet G; Torregrosa-Diaz JM; Terriou L; Algayres JP; Urbain F; Yakoub-Agha I; Farge D
Bull Cancer; 2023 Feb; 110(2S):S97-S107. PubMed ID: 36658011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
